Med Business World

Your source for healthcare business

Dapagliflozin

IMA to Organize Conference on “Multispecialities Cardio Reno Metabolic & HF in Women” Tomorrow

A day long “Multispecialities Cardio Reno Metabolic Conference & HF in Women” is being organized by Indian Medical Association (IMA), New Delhi Branch, Healthy Heart Society & Max Super Speciality Hospital, Saket, tomorrow at IIC, Max Mueller Marg, Lodhi Estate,…

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial

Detailed results from the DELIVER Phase III trial showed AstraZeneca’s dapagliflozin significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo. The results…